Assignee
VELICEPT THERAPEUTICS INC
US·9 granted patents·4 pending applications·66 citations·filing 2013–2020
Top patents by PatentIndex Score
13 records- 0194US10065922B2Solabegron zwitterion and uses thereofVELICEPT THERAPEUTICS INC·Filed 2016·Granted Sep 4, 2018·9 cites·126 claims
- 0293US10221126B2Solabegron zwitterion and uses thereofVELICEPT THERAPEUTICS INC·Filed 2018·Granted Mar 5, 2019·4 cites·9 claims
- 0393US9907767B2Pharmaceutical compositions and the treatment of overactive bladderVELICEPT THERAPEUTICS INC·Filed 2017·Granted Mar 6, 2018·10 cites·42 claims
- 0492US10350182B2Pharmaceutical compositions and the treatment of overactive bladderVELICEPT THERAPEUTICS INC·Filed 2018·Granted Jul 16, 2019·6 cites·16 claims
- 0592US9522129B2Pharmaceutical CombinationVELICEPT THERAPEUTICS INC·Filed 2013·Granted Dec 20, 2016·14 cites·16 claims
- 0690US10844004B2Solabegron zwitterion and uses thereofVELICEPT THERAPEUTICS INC·Filed 2019·Granted Nov 24, 2020·2 cites·13 claims
- 0790US9956194B2Compositions and methods of using modified release solabegron for lower urinary tract symptomsVELICEPT THERAPEUTICS INC·Filed 2015·Granted May 1, 2018·18 cites·60 claims
- 0884US10668034B2Pharmaceutical compositions and the treatment of overactive bladderVELICEPT THERAPEUTICS INC·Filed 2019·Granted Jun 2, 2020·1 cites·16 claims
- 0983US10751311B2Compositions and methods of using modified release solabegron for lower urinary tract symptomsVELICEPT THERAPEUTICS INC·Filed 2018·Granted Aug 25, 2020·2 cites·16 claims
- 1065US2020246292A1Pharmaceutical compositions and the treatment of overactive bladderVELICEPT THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1154US2017035716A1Method of using solabegronVELICEPT THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 1242US2017348288A1Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladderVELICEPT THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 1342US2017348263A1Compositions and methods of using modified release solabegron for lower urinary tract symptomsVELICEPT THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →